SCHEMBL2996047

SCHEMBL2996047

O=C(Cc1ccc(F)cc1)Nc1ccc(Cl)c(NC2=NC(=O)C(=Cc3ccc4ncccc4c3)S2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 1/20 0.42
MAPT P10636 3/20 0.41
ORAI1 Q96D31 2/20 0.40
DYRK3 O43781 2/20 0.39
HDAC3 O15379 2/20 0.39
ANO1 Q5XXA6 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HDAC4 P56524 2/20 0.37
CLK1 P49759 2/20 0.37
HDAC8 Q9BY41 1/20 0.37
PIK3CD O00329 1/20 0.37
PIM1 P11309 1/20 0.37
CSNK2A2 P19784 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2996046 1.00 CISD1 (0.42) CISD1MAPTORAI1DYRK3HDAC3
Trifluoroacetic Acid SCHEMBL4089474 0.96 CISD1 (0.39) CISD1MAPTORAI1DYRK3HDAC3
Trifluoroacetic Acid SCHEMBL4089468 0.96 CISD1 (0.39) CISD1MAPTORAI1DYRK3HDAC3
SCHEMBL2998928 0.88 LMNA (0.44) CISD1MAPTHDAC3ANO1ALDH1A1
SCHEMBL2998932 0.88 LMNA (0.44) CISD1MAPTHDAC3ANO1ALDH1A1
SCHEMBL2993651 0.88 TSHR (0.42) CISD1MAPTDYRK3HDAC3ALDH1A1
SCHEMBL2993647 0.88 TSHR (0.42) CISD1MAPTDYRK3HDAC3ALDH1A1
SCHEMBL4942268 0.88 ALDH1A1 (0.43) CISD1MAPTDYRK3HDAC3ALDH1A1
SCHEMBL4947101 0.87 DYRK3 (0.42) CISD1MAPTDYRK3HDAC3ALDH1A1
SCHEMBL4946166 0.87 DYRK3 (0.42) CISD1MAPTDYRK3HDAC3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US claimed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP claimed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 CISD1 3370/4885MAPT 721/4885ORAI1 385/4885
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 CISD1 3112/4885MAPT 1880/4885ORAI1 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.